John Lyne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Lyne has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Anne Marie Doherty
Mater Misericordiae University Hospital
3 shared publications - Fiona McNicholas
School of Medicine & Medical Science, University College Dublin, Dublin, Ireland
3 shared publications - Philipp Homan
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland
3 shared publications - Blánaid Gavin
University College Dublin
2 shared publications Brian Hallahan
University College Hospital Galway, Mental Health Services
2 shared publicationsBrian O'DOnoghue
Department of Psychiatry, Royal College of Surgeons, 123 St Stephen's Green, Dublin 2, Ireland; Department of Psychiatry, University College Dublin, Belfield, Dublin 4, Ireland
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , e103
Advancing the use of artificial intelligence in psychiatry: The need for international collaboration
Challenging macrotrends in recent decades have characterised population mental health across the globe, with apparent deterioration in adolescent mental health, as well as underfunded, inequitable, and inefficient psychiatric care systems [1]. Unnecessary delays to treatment are widespread, with systemic difficulties, such as clinician burnout, a dearth of funding, and staff shortages, negatively impacting mental health care across Europe and beyond [2]. With limited clinician time and resources available, new methods for improving mental health care are an urgent priority. Digital technologies, and particularly recent advances in the capabilities of artificial intelligence (AI), offer potential to address some of these challenges, thereby transforming approaches to mental health care.
- 19 October 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , e103
Open AccessAdvancing the use of artificial intelligence in psychiatry: The need for international collaboration
Challenging macrotrends in recent decades have characterised population mental health across the globe, with apparent deterioration in adolescent mental health, as well as underfunded, inequitable, and inefficient psychiatric care systems [1]. Unnecessary delays to treatment are widespread, with systemic difficulties, such as clinician burnout, a dearth of funding, and staff shortages, negatively impacting mental health care across Europe and beyond [2]. With limited clinician time and resources available, new methods for improving mental health care are an urgent priority. Digital technologies, and particularly recent advances in the capabilities of artificial intelligence (AI), offer potential to address some of these challenges, thereby transforming approaches to mental health care.
- Open Access
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 13 (1) , e92192
Using AI to Detect Psychosis Relapse: Scoping Review
Background: Psychotic disorder represents a leading cause of disability worldwide, and relapse in psychosis is common. Artificial intelligence (AI) is increasingly recognized as a method that could aid clinical monitoring for individuals experiencing psychosis. Objective: This review aims to map the existing literature on AI-based approaches—including machine learning, deep learning, and natural language processing—used to detect relapse in individuals with psychotic disorders. Methods: A systematic search strategy was conducted on PubMed, PsycINFO, and Embase up to January 7, 2026. Observational studies, randomized controlled trials, and quasi-experimental studies that used AI methods to detect relapse in psychosis were eligible for inclusion. Screening and data extraction procedures were conducted by at least 2 reviewers working independently. Findings were extracted, charted, and described using narrative synthesis based on data extraction and consensus meetings with the research team. The scoping review was prospectively registered with the Open Science Framework. Results: Relevant studies identified (N=10) included the use of digital tools such as smartphone- and smartwatch-based monitoring, ecological momentary assessment tools, social media activity, and internet searches. Digital phenotyping via smartphones and wearables emerged as the most common method for data collection. The efficacy of AI models varied with sensitivity (or recall) ranging from 0.25 to 0.77 and specificity (or precision) ranging from 0.06 to 0.88. The reported area under the receiver operating characteristic curve for models ranged from 0.63 to 0.78. AI models were heterogeneous across studies, and most study findings were not replicated. Conclusions: This scoping review highlights both the promise and the current limitations of AI in psychosis relapse detection. Passive digital phenotyping research in the detection of psychosis relapse has progressed, and personalized approaches with individual-level modeling show promise; however, further studies need to include larger numbers of participants and should incorporate methods such as large language models. Future studies will require large collaborations aimed at delivering AI methods for use in real-world clinical practice.
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 13 (1) , e92192
Open AccessUsing AI to Detect Psychosis Relapse: Scoping Review
Background: Psychotic disorder represents a leading cause of disability worldwide, and relapse in psychosis is common. Artificial intelligence (AI) is increasingly recognized as a method that could aid clinical monitoring for individuals experiencing psychosis. Objective: This review aims to map the existing literature on AI-based approaches—including machine learning, deep learning, and natural language processing—used to detect relapse in individuals with psychotic disorders. Methods: A systematic search strategy was conducted on PubMed, PsycINFO, and Embase up to January 7, 2026. Observational studies, randomized controlled trials, and quasi-experimental studies that used AI methods to detect relapse in psychosis were eligible for inclusion. Screening and data extraction procedures were conducted by at least 2 reviewers working independently. Findings were extracted, charted, and described using narrative synthesis based on data extraction and consensus meetings with the research team. The scoping review was prospectively registered with the Open Science Framework. Results: Relevant studies identified (N=10) included the use of digital tools such as smartphone- and smartwatch-based monitoring, ecological momentary assessment tools, social media activity, and internet searches. Digital phenotyping via smartphones and wearables emerged as the most common method for data collection. The efficacy of AI models varied with sensitivity (or recall) ranging from 0.25 to 0.77 and specificity (or precision) ranging from 0.06 to 0.88. The reported area under the receiver operating characteristic curve for models ranged from 0.63 to 0.78. AI models were heterogeneous across studies, and most study findings were not replicated. Conclusions: This scoping review highlights both the promise and the current limitations of AI in psychosis relapse detection. Passive digital phenotyping research in the detection of psychosis relapse has progressed, and personalized approaches with individual-level modeling show promise; however, further studies need to include larger numbers of participants and should incorporate methods such as large language models. Future studies will require large collaborations aimed at delivering AI methods for use in real-world clinical practice.
- Open Access
- 25 March 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-14
The impact of the COVID-19 pandemic on psychiatric morbidity and emergency mental health presentations in Ireland: a systematic review
Objectives: To examine the impact the COVID-19 pandemic in Ireland on symptoms and functioning in individuals across a range of mental health disorders. Methods: A systematic bibliographic search of case reports, cross-sectional and longitudinal studies was conducted between March 12 th , 2020, and December 20 th , 2024, among studies evaluating the impact of the COVID-19 pandemic on symptoms and functioning for individuals with pre-existing mental health disorders and for those who presented with self-harm or died by probable suicide in the Republic of Ireland. Studies were independently screened by two reviewers according to inclusion and exclusion criteria, with selected variables extracted and summarised. Risk of bias assessments and narrative synthesis of included studies were conducted. Results: Twenty-eight studies met inclusion criteria. Findings were heterogeneous and disorder specific. An increase in presentations of self-harm, anxiety disorders, and eating disorders to child and adolescent mental health services and emergency departments was noted, with relative stability of symptoms in other cohorts including bipolar disorder and treatment-resistant schizophrenia. Significant symptom deterioration, with poor quality of life and functioning was demonstrated in individuals with emotionally unstable personality disorder both cross-sectionally and longitudinally. Conclusions: Most people with pre-existing mental disorders did not experience significant exacerbation associated with the pandemic, with exception of those with eating disorders and EUPD.
- 25 March 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-14
Open AccessThe impact of the COVID-19 pandemic on psychiatric morbidity and emergency mental health presentations in Ireland: a systematic review
Objectives: To examine the impact the COVID-19 pandemic in Ireland on symptoms and functioning in individuals across a range of mental health disorders. Methods: A systematic bibliographic search of case reports, cross-sectional and longitudinal studies was conducted between March 12 th , 2020, and December 20 th , 2024, among studies evaluating the impact of the COVID-19 pandemic on symptoms and functioning for individuals with pre-existing mental health disorders and for those who presented with self-harm or died by probable suicide in the Republic of Ireland. Studies were independently screened by two reviewers according to inclusion and exclusion criteria, with selected variables extracted and summarised. Risk of bias assessments and narrative synthesis of included studies were conducted. Results: Twenty-eight studies met inclusion criteria. Findings were heterogeneous and disorder specific. An increase in presentations of self-harm, anxiety disorders, and eating disorders to child and adolescent mental health services and emergency departments was noted, with relative stability of symptoms in other cohorts including bipolar disorder and treatment-resistant schizophrenia. Significant symptom deterioration, with poor quality of life and functioning was demonstrated in individuals with emotionally unstable personality disorder both cross-sectionally and longitudinally. Conclusions: Most people with pre-existing mental disorders did not experience significant exacerbation associated with the pandemic, with exception of those with eating disorders and EUPD.
- Open Access
TRUSTING: An International Multicenter Observational Study of Speech-Based Relapse Prediction in Psychosis Using Explainable AI
Introduction: The course of psychotic disorders typically involves relapses. Early warning signs vary between individuals and are difficult to detect in clinical practice, especially in outpatient settings. Speech provides a quantitative clinical marker for detecting such early warning signs. The EU Horizon project TRUSTING (A TRUSTworthy speech-based AI monitoring system for the prediction of relapse in individuals with schizophrenia) aims to develop and evaluate a speech-based monitoring system for predicting imminent psychotic relapses. The study will examine the potential for prospective relapse prediction, and feasibility and usability of the monitoring system. Methods and analysis: In this multicenter observational study, n = 240 remitted and at-risk-of-relapse adults with psychotic disorders and a comparison group with n = 120 healthy participants (matched by age and sex) will be examined at six sites and in six different languages (German, French, Dutch, English, Czech, and Turkish). The follow-up period is 6 months. The TRUSTING smartphone app will be used to collect weekly voice recordings through speech tasks; information on medication adherence, substance use, mood, anxiety, and sleep quality; and motor data from a tapping task. Primary endpoints encompass model performance for relapse prediction, user adherence, transcription quality, usability of recordings, and overall system usability. The primary analysis of user adherence, transcription quality, usability of recordings, and overall system usability will be an unadjusted description of the respective proportions using 95% Wilson confidence intervals. Regarding relapse prediction, the predictive value of the risk estimates for relapse occurrence will be assessed using the area under the receiver operating characteristic curve. Exploratory analysis will be performed on potential speech-based markers associated with relapse risk. Ethics and dissemination: This study has been approved by swissethics (BASEC number: 2025-01177). Findings from this project will be disseminated through peer-reviewed journal publications and presentations at relevant scientific conferences, as well as public events related to mental health. ARTICLE SUMMARY: Strengths and limitations of this study: – International multicenter study spanning six sites, six languages, and five countries, enabling evaluation of the cross-linguistic generalizability of speech-based relapse prediction models in psychosis. – Human oversight enabling head-to-head comparison between human judgment and machine-generated predictions of relapse risk and ensuring the study’s safety and trustworthiness. – Involvement of people with lived experience of psychosis in both study and system design. – Inclusion of a matched control group to study intra- and interindividual variations in speech features over multiple measurements. – Insights into the feasibility of implementing artificial intelligence (AI)-based transcription and speech analysis in routine mental healthcare, and exploration of novel speech-based markers associated with relapse risk to enhance prediction, understanding, and prevention of relapse in the future.
Open AccessTRUSTING: An International Multicenter Observational Study of Speech-Based Relapse Prediction in Psychosis Using Explainable AI
Introduction: The course of psychotic disorders typically involves relapses. Early warning signs vary between individuals and are difficult to detect in clinical practice, especially in outpatient settings. Speech provides a quantitative clinical marker for detecting such early warning signs. The EU Horizon project TRUSTING (A TRUSTworthy speech-based AI monitoring system for the prediction of relapse in individuals with schizophrenia) aims to develop and evaluate a speech-based monitoring system for predicting imminent psychotic relapses. The study will examine the potential for prospective relapse prediction, and feasibility and usability of the monitoring system. Methods and analysis: In this multicenter observational study, n = 240 remitted and at-risk-of-relapse adults with psychotic disorders and a comparison group with n = 120 healthy participants (matched by age and sex) will be examined at six sites and in six different languages (German, French, Dutch, English, Czech, and Turkish). The follow-up period is 6 months. The TRUSTING smartphone app will be used to collect weekly voice recordings through speech tasks; information on medication adherence, substance use, mood, anxiety, and sleep quality; and motor data from a tapping task. Primary endpoints encompass model performance for relapse prediction, user adherence, transcription quality, usability of recordings, and overall system usability. The primary analysis of user adherence, transcription quality, usability of recordings, and overall system usability will be an unadjusted description of the respective proportions using 95% Wilson confidence intervals. Regarding relapse prediction, the predictive value of the risk estimates for relapse occurrence will be assessed using the area under the receiver operating characteristic curve. Exploratory analysis will be performed on potential speech-based markers associated with relapse risk. Ethics and dissemination: This study has been approved by swissethics (BASEC number: 2025-01177). Findings from this project will be disseminated through peer-reviewed journal publications and presentations at relevant scientific conferences, as well as public events related to mental health. ARTICLE SUMMARY: Strengths and limitations of this study: – International multicenter study spanning six sites, six languages, and five countries, enabling evaluation of the cross-linguistic generalizability of speech-based relapse prediction models in psychosis. – Human oversight enabling head-to-head comparison between human judgment and machine-generated predictions of relapse risk and ensuring the study’s safety and trustworthiness. – Involvement of people with lived experience of psychosis in both study and system design. – Inclusion of a matched control group to study intra- and interindividual variations in speech features over multiple measurements. – Insights into the feasibility of implementing artificial intelligence (AI)-based transcription and speech analysis in routine mental healthcare, and exploration of novel speech-based markers associated with relapse risk to enhance prediction, understanding, and prevention of relapse in the future.
- Open Access
- 1 September 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (3) , 179-181
Progress and change for the Irish Journal of Psychological Medicine
The Irish Journal of Psychological Medicine (IJPM), a journal founded with an Irish identity, has progressed over four decades into a journal of both national and international relevance. The IJPM, now the official scientific journal of the College of Psychiatrists of Ireland, works collaboratively with many stakeholders including policymakers, those working in mental health services and those who have experienced mental illness. The journal aims to publish scientific literature and research which will help service users, clinicians and mental health services, and which can inform mental health policy. In this editorial the outgoing and incoming Editors-in-Chief reflect on how the journal has developed in recent times, and how the journal can progress at a time of societal change and technological advancement.
- 1 September 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (3) , 179-181
Open AccessProgress and change for the Irish Journal of Psychological Medicine
The Irish Journal of Psychological Medicine (IJPM), a journal founded with an Irish identity, has progressed over four decades into a journal of both national and international relevance. The IJPM, now the official scientific journal of the College of Psychiatrists of Ireland, works collaboratively with many stakeholders including policymakers, those working in mental health services and those who have experienced mental illness. The journal aims to publish scientific literature and research which will help service users, clinicians and mental health services, and which can inform mental health policy. In this editorial the outgoing and incoming Editors-in-Chief reflect on how the journal has developed in recent times, and how the journal can progress at a time of societal change and technological advancement.
- Open Access
- 13 August 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-7
Fighting fire with fire: the need to use metformin to combat antipsychotic-induced weight gain and metabolic complications
Background: Second-generation antipsychotics (SGAs) are moderately effective treatments for psychotic disorders but are associated with significant weight gain and metabolic complications. These contribute to a nearly 20-year reduction in life expectancy for individuals with enduring psychotic illness. Weight gain can also negatively impact adherence, increase relapse risk, and worsen psychosocial outcomes. Aims: To highlight the mechanisms underlying antipsychotic-induced weight gain (AIWG), examine pharmacological strategies for its prevention and treatment, and argue for the early use of metformin. Method: This perspective article synthesises current evidence on the pathophysiology of AIWG and evaluates the role of metformin in mitigating these effects. Conclusions: Weight gain can occur rapidly after initiating antipsychotic treatment, particularly in young people and those prescribed antipsychotics for non-psychotic indications. Presentation and response to interventions vary. Of all pharmacological strategies, metformin has the most robust evidence for both prevention and treatment of AIWG. It is a well-tolerated, low-cost antihyperglycaemic agent with an established safety profile. Metformin should be considered early in the course of antipsychotic treatment for all individuals, regardless of diagnosis, to prevent clinically significant weight gain and reduce long-term health risks. Early intervention may improve adherence, reduce relapse, and enhance overall quality of life.
- 13 August 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-7
Open AccessFighting fire with fire: the need to use metformin to combat antipsychotic-induced weight gain and metabolic complications
Background: Second-generation antipsychotics (SGAs) are moderately effective treatments for psychotic disorders but are associated with significant weight gain and metabolic complications. These contribute to a nearly 20-year reduction in life expectancy for individuals with enduring psychotic illness. Weight gain can also negatively impact adherence, increase relapse risk, and worsen psychosocial outcomes. Aims: To highlight the mechanisms underlying antipsychotic-induced weight gain (AIWG), examine pharmacological strategies for its prevention and treatment, and argue for the early use of metformin. Method: This perspective article synthesises current evidence on the pathophysiology of AIWG and evaluates the role of metformin in mitigating these effects. Conclusions: Weight gain can occur rapidly after initiating antipsychotic treatment, particularly in young people and those prescribed antipsychotics for non-psychotic indications. Presentation and response to interventions vary. Of all pharmacological strategies, metformin has the most robust evidence for both prevention and treatment of AIWG. It is a well-tolerated, low-cost antihyperglycaemic agent with an established safety profile. Metformin should be considered early in the course of antipsychotic treatment for all individuals, regardless of diagnosis, to prevent clinically significant weight gain and reduce long-term health risks. Early intervention may improve adherence, reduce relapse, and enhance overall quality of life.
- Open Access
- 1 June 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (2) , 95-96
Modernising mental health services and rising mental health challenges in youth
Our June 2025 issue covers a number of interesting topics including themes related to telepsychiatry, mental health during COVID-19 and a consideration of some of the increasing challenges in child and adolescent mental health services.
- 1 June 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (2) , 95-96
Open AccessModernising mental health services and rising mental health challenges in youth
Our June 2025 issue covers a number of interesting topics including themes related to telepsychiatry, mental health during COVID-19 and a consideration of some of the increasing challenges in child and adolescent mental health services.
- Open Access
- 31 March 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 279, 40-49
Negative symptoms in psychosis: A scoping review of qualitative studies
- 31 March 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 279, 40-49
Open AccessNegative symptoms in psychosis: A scoping review of qualitative studies
- Open Access
- 28 March 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (1) , 1-2
Mental health perspectives across services and across the lifespan
- 28 March 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (1) , 1-2
Open AccessMental health perspectives across services and across the lifespan
- Open Access
- 25 March 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (3) , 221-226
Impact of nutritional interventions on quality of life in schizophrenia spectrum disorders: a scoping review
Objectives: Schizophrenia is a chronic condition that requires long-term management. Quality of life is an important outcome measure for individuals diagnosed with schizophrenia; it can be tracked over time allowing evaluation of whether interventions lead to sustainable improvements. Nutrition and dietary interventions are an underutilized treatment for tackling the metabolic consequences of mental illness, which is now recognized as having increased importance in the management of schizophrenia. This study examines the impact of nutrition and dietary interventions on quality of life outcomes for those with schizophrenia. Methods: A systematic review of the literature was conducted, assessing the impact of nutritional interventions on quality of life outcomes in individuals with a diagnosis of schizophrenia. Results: A total of 982 articles were screened, of which nine articles met the inclusion criteria. Quality of life measures varied across studies, which made comparison across studies challenging. Previous studies had relatively small sample sizes and did not have long follow-up durations. Some of the studies found that dietary interventions such as counselling, weight management programs, food diaries and nutritional education improved quality of life, whereas others did not detect any effect. Conclusions: The review provides preliminary evidence that nutrition and dietary interventions may benefit quality of life among individuals with schizophrenia. There were however substantial limitations in studies highlighting the need for further research. The paper also highlights the need to standardize assessment tools for future quality-of-life research.
- 25 March 2025
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- Vol. 42 (3) , 221-226
Open AccessImpact of nutritional interventions on quality of life in schizophrenia spectrum disorders: a scoping review
Objectives: Schizophrenia is a chronic condition that requires long-term management. Quality of life is an important outcome measure for individuals diagnosed with schizophrenia; it can be tracked over time allowing evaluation of whether interventions lead to sustainable improvements. Nutrition and dietary interventions are an underutilized treatment for tackling the metabolic consequences of mental illness, which is now recognized as having increased importance in the management of schizophrenia. This study examines the impact of nutrition and dietary interventions on quality of life outcomes for those with schizophrenia. Methods: A systematic review of the literature was conducted, assessing the impact of nutritional interventions on quality of life outcomes in individuals with a diagnosis of schizophrenia. Results: A total of 982 articles were screened, of which nine articles met the inclusion criteria. Quality of life measures varied across studies, which made comparison across studies challenging. Previous studies had relatively small sample sizes and did not have long follow-up durations. Some of the studies found that dietary interventions such as counselling, weight management programs, food diaries and nutritional education improved quality of life, whereas others did not detect any effect. Conclusions: The review provides preliminary evidence that nutrition and dietary interventions may benefit quality of life among individuals with schizophrenia. There were however substantial limitations in studies highlighting the need for further research. The paper also highlights the need to standardize assessment tools for future quality-of-life research.